Cyclophosphamide cyp

PLGA (lactic acid:glycolic acid = 50:50; MW = 48,000) was obtained from Evonik Industries (Essen, Germany). Dichloromethane (DCM; >99.5%) and N,N‐dimethylformamide (DMF, >99.5%) were purchased from DaeJung (Siheung, Korea). Acetonitrile (ACN; >99.9%) and lidocaine were obtained from J. T. Bakers (Phillisburg, NJ) and Tokyo Chemical Industry (Tokyo, Japan), respectively. Polethylene catheters (SP‐45 and SP‐61) were obtained from Natsume Seisakusho (Tokyo, Japan). Surgical sutures (4–0 and 5–0 silk) and cotton bandages were purchased from Ailee (Seoul, Korea) and Bandgold (Ansan, Gyeonggi‐do, Korea), respectively. Cyclophosphamide (CYP) was purchased from Sigma‐Aldrich (MO). Anti‐COX‐2 polyclonal antibody (ab 15191), anti‐IL‐6 polyclonal antibody (ab 6672), anti‐NGF polyclonal antibody (ab 6199), and rat IL‐6 ELISA Kit (ab 234570) were obtained from Abcam (MA). DAB kit was purchased from Vector Laboratories (CA). Hematoxylin‐1 and bluing solution were purchased from the Korea Standard (Seongnam, Korea). Revoscript rt premix (25086) was purchased from Invitrogen (Carlsbad, CA). LightCycler ® 480 SYBR Green was purchased from Roche (Basel, Switzerland).

Cyclophosphamide (CYP, 50 mg/kg; Sigma, St. Louis, MO) was intraperitoneally injected every three days for seven days (injection on days 1, 4, and 7; three times in total) to establish the cystitis rat model. Intrathecal injection of a γ-secretase inhibitor, DAPT (MedChemExpress, Princeton, NJ), was used to inhibit the release of NICD and Notch1 signaling transduction.

Cyclophosphamide (CYP) was purchased from Sigma–Aldrich Chemicals Co., St. Louis, USA. Hesperidin (HSP) as a pale yellow powder, was purchased from Sigma˗Egypt, (Cairo, Egypt). CYP and HSP were dissolved in normal saline to be administered to rats.